What changed from existing technology?
This study found that a molecule called Neuromedin U changes how immune cells behave in a type of aggressive prostate cancer, making them less able to fight the cancer.
This is the first study to link Neuromedin U to immune suppression in neuroendocrine prostate cancer, suggesting a new mechanism for tumor progression.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
p = 3.62 × 10−9). Analysis of a large cohort of human patient samples revealed that NMU was highly expressed in early and late stage prostate cancer, prefer
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
The findings suggest that targeting Neuromedin U could be a potential strategy to enhance anti-tumor immunity in neuroendocrine prostate cancer.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.